Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
CAMBRIDGE, Mass. — Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into defi
(Financial Post, 2025-12-11T18:48:47Z)